MiniMed Group, Inc. Common Stock (MMED) Stock Competitors & Peer Comparison
See (MMED) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Care Facilities Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MMED | $14.26 | +15.93% | 4.1B | -11.40 | -$1.27 | N/A |
| HCA | $363.23 | -1.12% | 80.6B | 12.51 | $29.03 | +0.81% |
| THC | $164.84 | +0.76% | 14.2B | 8.56 | $19.24 | N/A |
| SOLV | $78.36 | +2.53% | 13.6B | 9.59 | $8.17 | N/A |
| DVA | $195.03 | +3.80% | 12.5B | 18.80 | $10.38 | N/A |
| FMS | $20.90 | +1.70% | 11.2B | 11.00 | $1.90 | +4.13% |
| EHC | $103.17 | +1.60% | 10.2B | 17.66 | $5.84 | +0.72% |
| ENSG | $166.68 | +0.59% | 9.7B | 27.10 | $6.15 | +0.16% |
| OSH | $39.00 | +0.08% | 9.5B | -17.65 | -$2.21 | N/A |
| UHS | $145.98 | +2.41% | 9.1B | 6.09 | $23.95 | +0.55% |
Stock Comparison
MMED vs HCA Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, HCA has a market cap of 80.6B. Regarding current trading prices, MMED is priced at $14.26, while HCA trades at $363.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas HCA's P/E ratio is 12.51. In terms of profitability, MMED's ROE is -0.09%, compared to HCA's ROE of -1.23%. Regarding short-term risk, MMED is more volatile compared to HCA. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check HCA's competition here
MMED vs THC Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, THC has a market cap of 14.2B. Regarding current trading prices, MMED is priced at $14.26, while THC trades at $164.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas THC's P/E ratio is 8.56. In terms of profitability, MMED's ROE is -0.09%, compared to THC's ROE of +0.41%. Regarding short-term risk, MMED is more volatile compared to THC. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check THC's competition here
MMED vs SOLV Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, SOLV has a market cap of 13.6B. Regarding current trading prices, MMED is priced at $14.26, while SOLV trades at $78.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas SOLV's P/E ratio is 9.59. In terms of profitability, MMED's ROE is -0.09%, compared to SOLV's ROE of +0.31%. Regarding short-term risk, MMED is more volatile compared to SOLV. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check SOLV's competition here
MMED vs DVA Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, DVA has a market cap of 12.5B. Regarding current trading prices, MMED is priced at $14.26, while DVA trades at $195.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas DVA's P/E ratio is 18.80. In terms of profitability, MMED's ROE is -0.09%, compared to DVA's ROE of -1.33%. Regarding short-term risk, MMED is more volatile compared to DVA. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check DVA's competition here
MMED vs FMS Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, FMS has a market cap of 11.2B. Regarding current trading prices, MMED is priced at $14.26, while FMS trades at $20.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas FMS's P/E ratio is 11.00. In terms of profitability, MMED's ROE is -0.09%, compared to FMS's ROE of +0.07%. Regarding short-term risk, MMED is more volatile compared to FMS. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check FMS's competition here
MMED vs EHC Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, EHC has a market cap of 10.2B. Regarding current trading prices, MMED is priced at $14.26, while EHC trades at $103.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas EHC's P/E ratio is 17.66. In terms of profitability, MMED's ROE is -0.09%, compared to EHC's ROE of +0.25%. Regarding short-term risk, MMED is more volatile compared to EHC. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check EHC's competition here
MMED vs ENSG Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, ENSG has a market cap of 9.7B. Regarding current trading prices, MMED is priced at $14.26, while ENSG trades at $166.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas ENSG's P/E ratio is 27.10. In terms of profitability, MMED's ROE is -0.09%, compared to ENSG's ROE of +0.17%. Regarding short-term risk, MMED is more volatile compared to ENSG. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check ENSG's competition here
MMED vs OSH Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, OSH has a market cap of 9.5B. Regarding current trading prices, MMED is priced at $14.26, while OSH trades at $39.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas OSH's P/E ratio is -17.65. In terms of profitability, MMED's ROE is -0.09%, compared to OSH's ROE of +4.64%. Regarding short-term risk, MMED is more volatile compared to OSH. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check OSH's competition here
MMED vs UHS Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, UHS has a market cap of 9.1B. Regarding current trading prices, MMED is priced at $14.26, while UHS trades at $145.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas UHS's P/E ratio is 6.09. In terms of profitability, MMED's ROE is -0.09%, compared to UHS's ROE of +0.21%. Regarding short-term risk, MMED is more volatile compared to UHS. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check UHS's competition here
MMED vs CHE Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, CHE has a market cap of 5.7B. Regarding current trading prices, MMED is priced at $14.26, while CHE trades at $426.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas CHE's P/E ratio is 23.29. In terms of profitability, MMED's ROE is -0.09%, compared to CHE's ROE of +0.25%. Regarding short-term risk, MMED is more volatile compared to CHE. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check CHE's competition here
MMED vs LHCG Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, LHCG has a market cap of 5.3B. Regarding current trading prices, MMED is priced at $14.26, while LHCG trades at $169.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas LHCG's P/E ratio is 82.83. In terms of profitability, MMED's ROE is -0.09%, compared to LHCG's ROE of +0.04%. Regarding short-term risk, MMED is more volatile compared to LHCG. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check LHCG's competition here
MMED vs AMED Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, AMED has a market cap of 3.3B. Regarding current trading prices, MMED is priced at $14.26, while AMED trades at $100.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas AMED's P/E ratio is 39.30. In terms of profitability, MMED's ROE is -0.09%, compared to AMED's ROE of +0.09%. Regarding short-term risk, MMED is more volatile compared to AMED. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check AMED's competition here
MMED vs OPCH Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, OPCH has a market cap of 3.2B. Regarding current trading prices, MMED is priced at $14.26, while OPCH trades at $20.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas OPCH's P/E ratio is 16.04. In terms of profitability, MMED's ROE is -0.09%, compared to OPCH's ROE of +0.15%. Regarding short-term risk, MMED is more volatile compared to OPCH. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check OPCH's competition here
MMED vs BKD Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, BKD has a market cap of 2.9B. Regarding current trading prices, MMED is priced at $14.26, while BKD trades at $12.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas BKD's P/E ratio is -14.07. In terms of profitability, MMED's ROE is -0.09%, compared to BKD's ROE of +401.19%. Regarding short-term risk, MMED is more volatile compared to BKD. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check BKD's competition here
MMED vs NHC Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, NHC has a market cap of 2.9B. Regarding current trading prices, MMED is priced at $14.26, while NHC trades at $186.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas NHC's P/E ratio is 23.72. In terms of profitability, MMED's ROE is -0.09%, compared to NHC's ROE of +0.12%. Regarding short-term risk, MMED is more volatile compared to NHC. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check NHC's competition here
MMED vs LFST Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, LFST has a market cap of 2.9B. Regarding current trading prices, MMED is priced at $14.26, while LFST trades at $7.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas LFST's P/E ratio is 125.00. In terms of profitability, MMED's ROE is -0.09%, compared to LFST's ROE of +0.02%. Regarding short-term risk, MMED is more volatile compared to LFST. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check LFST's competition here
MMED vs ACHC Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, ACHC has a market cap of 2.4B. Regarding current trading prices, MMED is priced at $14.26, while ACHC trades at $25.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas ACHC's P/E ratio is -2.11. In terms of profitability, MMED's ROE is -0.09%, compared to ACHC's ROE of -0.44%. Regarding short-term risk, MMED is more volatile compared to ACHC. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check ACHC's competition here
MMED vs SEM Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, SEM has a market cap of 2B. Regarding current trading prices, MMED is priced at $14.26, while SEM trades at $16.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas SEM's P/E ratio is 15.41. In terms of profitability, MMED's ROE is -0.09%, compared to SEM's ROE of +0.08%. Regarding short-term risk, MMED is more volatile compared to SEM. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check SEM's competition here
MMED vs AMEH Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, AMEH has a market cap of 1.8B. Regarding current trading prices, MMED is priced at $14.26, while AMEH trades at $40.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas AMEH's P/E ratio is 39.25. In terms of profitability, MMED's ROE is -0.09%, compared to AMEH's ROE of +0.04%. Regarding short-term risk, MMED is more volatile compared to AMEH. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check AMEH's competition here
MMED vs ASTH Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, ASTH has a market cap of 1.8B. Regarding current trading prices, MMED is priced at $14.26, while ASTH trades at $36.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas ASTH's P/E ratio is 60.16. In terms of profitability, MMED's ROE is -0.09%, compared to ASTH's ROE of +0.04%. Regarding short-term risk, MMED is more volatile compared to ASTH. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check ASTH's competition here
MMED vs MD Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, MD has a market cap of 1.8B. Regarding current trading prices, MMED is priced at $14.26, while MD trades at $21.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas MD's P/E ratio is 10.60. In terms of profitability, MMED's ROE is -0.09%, compared to MD's ROE of +0.20%. Regarding short-term risk, MMED is more volatile compared to MD. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check MD's competition here
MMED vs SGRY Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, SGRY has a market cap of 1.8B. Regarding current trading prices, MMED is priced at $14.26, while SGRY trades at $13.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas SGRY's P/E ratio is -22.90. In terms of profitability, MMED's ROE is -0.09%, compared to SGRY's ROE of -0.04%. Regarding short-term risk, MMED is more volatile compared to SGRY. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check SGRY's competition here
MMED vs ADUS Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, ADUS has a market cap of 1.7B. Regarding current trading prices, MMED is priced at $14.26, while ADUS trades at $88.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas ADUS's P/E ratio is 16.33. In terms of profitability, MMED's ROE is -0.09%, compared to ADUS's ROE of +0.09%. Regarding short-term risk, MMED is more volatile compared to ADUS. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check ADUS's competition here
MMED vs AVAH Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, AVAH has a market cap of 1.5B. Regarding current trading prices, MMED is priced at $14.26, while AVAH trades at $6.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas AVAH's P/E ratio is 5.60. In terms of profitability, MMED's ROE is -0.09%, compared to AVAH's ROE of +2.41%. Regarding short-term risk, MMED is more volatile compared to AVAH. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check AVAH's competition here
MMED vs HCSG Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, HCSG has a market cap of 1.4B. Regarding current trading prices, MMED is priced at $14.26, while HCSG trades at $20.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas HCSG's P/E ratio is 21.25. In terms of profitability, MMED's ROE is -0.09%, compared to HCSG's ROE of +0.14%. Regarding short-term risk, MMED is more volatile compared to HCSG. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check HCSG's competition here
MMED vs AGL Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, AGL has a market cap of 1.4B. Regarding current trading prices, MMED is priced at $14.26, while AGL trades at $82.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas AGL's P/E ratio is -3.66. In terms of profitability, MMED's ROE is -0.09%, compared to AGL's ROE of -1.46%. Regarding short-term risk, MMED is more volatile compared to AGL. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check AGL's competition here
MMED vs BKDT Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, BKDT has a market cap of 1.2B. Regarding current trading prices, MMED is priced at $14.26, while BKDT trades at $77.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas BKDT's P/E ratio is N/A. In terms of profitability, MMED's ROE is -0.09%, compared to BKDT's ROE of +401.19%. Regarding short-term risk, MMED is more volatile compared to BKDT. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check BKDT's competition here
MMED vs CMPS Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, CMPS has a market cap of 1.2B. Regarding current trading prices, MMED is priced at $14.26, while CMPS trades at $12.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas CMPS's P/E ratio is -4.04. In terms of profitability, MMED's ROE is -0.09%, compared to CMPS's ROE of -1.51%. Regarding short-term risk, MMED is more volatile compared to CMPS. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check CMPS's competition here
MMED vs AMN Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, AMN has a market cap of 1.2B. Regarding current trading prices, MMED is priced at $14.26, while AMN trades at $30.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas AMN's P/E ratio is -35.25. In terms of profitability, MMED's ROE is -0.09%, compared to AMN's ROE of -0.05%. Regarding short-term risk, MMED is more volatile compared to AMN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check AMN's competition here
MMED vs ARDT Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, ARDT has a market cap of 1.1B. Regarding current trading prices, MMED is priced at $14.26, while ARDT trades at $7.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas ARDT's P/E ratio is 8.21. In terms of profitability, MMED's ROE is -0.09%, compared to ARDT's ROE of +0.09%. Regarding short-term risk, MMED is more volatile compared to ARDT. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check ARDT's competition here
MMED vs PNTG Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, PNTG has a market cap of 1.1B. Regarding current trading prices, MMED is priced at $14.26, while PNTG trades at $30.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas PNTG's P/E ratio is 35.29. In terms of profitability, MMED's ROE is -0.09%, compared to PNTG's ROE of +0.09%. Regarding short-term risk, MMED is more volatile compared to PNTG. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check PNTG's competition here
MMED vs INNV Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, INNV has a market cap of 961M. Regarding current trading prices, MMED is priced at $14.26, while INNV trades at $7.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas INNV's P/E ratio is -88.50. In terms of profitability, MMED's ROE is -0.09%, compared to INNV's ROE of -0.09%. Regarding short-term risk, MMED is more volatile compared to INNV. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check INNV's competition here
MMED vs USPH Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, USPH has a market cap of 943.3M. Regarding current trading prices, MMED is priced at $14.26, while USPH trades at $61.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas USPH's P/E ratio is 123.96. In terms of profitability, MMED's ROE is -0.09%, compared to USPH's ROE of +0.00%. Regarding short-term risk, MMED is more volatile compared to USPH. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check USPH's competition here
MMED vs TALK Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, TALK has a market cap of 872.7M. Regarding current trading prices, MMED is priced at $14.26, while TALK trades at $5.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas TALK's P/E ratio is 130.25. In terms of profitability, MMED's ROE is -0.09%, compared to TALK's ROE of +0.01%. Regarding short-term risk, MMED is more volatile compared to TALK. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check TALK's competition here
MMED vs FSHCX Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, FSHCX has a market cap of 820.5M. Regarding current trading prices, MMED is priced at $14.26, while FSHCX trades at $105.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas FSHCX's P/E ratio is N/A. In terms of profitability, MMED's ROE is -0.09%, compared to FSHCX's ROE of N/A. Regarding short-term risk, MMED is more volatile compared to FSHCX. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check FSHCX's competition here
MMED vs EHAB Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, EHAB has a market cap of 706.9M. Regarding current trading prices, MMED is priced at $14.26, while EHAB trades at $13.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas EHAB's P/E ratio is -197.14. In terms of profitability, MMED's ROE is -0.09%, compared to EHAB's ROE of -0.01%. Regarding short-term risk, MMED is more volatile compared to EHAB. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check EHAB's competition here
MMED vs SNDA Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, SNDA has a market cap of 671.8M. Regarding current trading prices, MMED is priced at $14.26, while SNDA trades at $33.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas SNDA's P/E ratio is -5.75. In terms of profitability, MMED's ROE is -0.09%, compared to SNDA's ROE of -0.35%. Regarding short-term risk, MMED is more volatile compared to SNDA. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check SNDA's competition here
MMED vs GMRS Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, GMRS has a market cap of 496.4M. Regarding current trading prices, MMED is priced at $14.26, while GMRS trades at $10.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas GMRS's P/E ratio is 5.64. In terms of profitability, MMED's ROE is -0.09%, compared to GMRS's ROE of N/A. Regarding short-term risk, MMED is more volatile compared to GMRS. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check GMRS's competition here
MMED vs MCTA Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, MCTA has a market cap of 445.6M. Regarding current trading prices, MMED is priced at $14.26, while MCTA trades at $29.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas MCTA's P/E ratio is 419.36. In terms of profitability, MMED's ROE is -0.09%, compared to MCTA's ROE of -2.33%. Regarding short-term risk, MMED is more volatile compared to MCTA. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check MCTA's competition here
MMED vs CCRN Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, CCRN has a market cap of 424.2M. Regarding current trading prices, MMED is priced at $14.26, while CCRN trades at $13.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas CCRN's P/E ratio is -4.30. In terms of profitability, MMED's ROE is -0.09%, compared to CCRN's ROE of -0.27%. Regarding short-term risk, MMED is more volatile compared to CCRN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check CCRN's competition here
MMED vs TOI Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, TOI has a market cap of 422.9M. Regarding current trading prices, MMED is priced at $14.26, while TOI trades at $4.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas TOI's P/E ratio is -12.09. In terms of profitability, MMED's ROE is -0.09%, compared to TOI's ROE of +3.27%. Regarding short-term risk, MMED is more volatile compared to TOI. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check TOI's competition here
MMED vs CYH Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, CYH has a market cap of 394.6M. Regarding current trading prices, MMED is priced at $14.26, while CYH trades at $2.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas CYH's P/E ratio is 0.81. In terms of profitability, MMED's ROE is -0.09%, compared to CYH's ROE of +0.06%. Regarding short-term risk, MMED is more volatile compared to CYH. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check CYH's competition here
MMED vs AIRS Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, AIRS has a market cap of 364.7M. Regarding current trading prices, MMED is priced at $14.26, while AIRS trades at $5.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas AIRS's P/E ratio is -30.41. In terms of profitability, MMED's ROE is -0.09%, compared to AIRS's ROE of -0.12%. Regarding short-term risk, MMED is more volatile compared to AIRS. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check AIRS's competition here
MMED vs AUNA Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, AUNA has a market cap of 332.4M. Regarding current trading prices, MMED is priced at $14.26, while AUNA trades at $4.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas AUNA's P/E ratio is 16.63. In terms of profitability, MMED's ROE is -0.09%, compared to AUNA's ROE of +0.04%. Regarding short-term risk, MMED is more volatile compared to AUNA. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check AUNA's competition here
MMED vs AONC Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, AONC has a market cap of 292.5M. Regarding current trading prices, MMED is priced at $14.26, while AONC trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas AONC's P/E ratio is -11.24. In terms of profitability, MMED's ROE is -0.09%, compared to AONC's ROE of +0.06%. Regarding short-term risk, MMED is more volatile compared to AONC. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check AONC's competition here
MMED vs CSU Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, CSU has a market cap of 223.7M. Regarding current trading prices, MMED is priced at $14.26, while CSU trades at $33.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas CSU's P/E ratio is 0.67. In terms of profitability, MMED's ROE is -0.09%, compared to CSU's ROE of -0.51%. Regarding short-term risk, MMED is more volatile compared to CSU. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check CSU's competition here
MMED vs JYNT Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, JYNT has a market cap of 117.9M. Regarding current trading prices, MMED is priced at $14.26, while JYNT trades at $8.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas JYNT's P/E ratio is 91.89. In terms of profitability, MMED's ROE is -0.09%, compared to JYNT's ROE of +0.17%. Regarding short-term risk, MMED is more volatile compared to JYNT. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check JYNT's competition here
MMED vs NAKAW Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, NAKAW has a market cap of 116.4M. Regarding current trading prices, MMED is priced at $14.26, while NAKAW trades at $15.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas NAKAW's P/E ratio is N/A. In terms of profitability, MMED's ROE is -0.09%, compared to NAKAW's ROE of -0.85%. Regarding short-term risk, MMED is less volatile compared to NAKAW. This indicates potentially lower risk in terms of short-term price fluctuations for MMED.Check NAKAW's competition here
MMED vs FVE Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, FVE has a market cap of 98.4M. Regarding current trading prices, MMED is priced at $14.26, while FVE trades at $2.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas FVE's P/E ratio is -5.64. In terms of profitability, MMED's ROE is -0.09%, compared to FVE's ROE of -0.15%. Regarding short-term risk, MMED is more volatile compared to FVE. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check FVE's competition here
MMED vs KDLYW Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, KDLYW has a market cap of 96.5M. Regarding current trading prices, MMED is priced at $14.26, while KDLYW trades at $18.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas KDLYW's P/E ratio is N/A. In terms of profitability, MMED's ROE is -0.09%, compared to KDLYW's ROE of -0.85%. Regarding short-term risk, MMED is less volatile compared to KDLYW. This indicates potentially lower risk in terms of short-term price fluctuations for MMED.Check KDLYW's competition here
MMED vs BTMD Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, BTMD has a market cap of 93.1M. Regarding current trading prices, MMED is priced at $14.26, while BTMD trades at $2.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas BTMD's P/E ratio is 4.91. In terms of profitability, MMED's ROE is -0.09%, compared to BTMD's ROE of -0.23%. Regarding short-term risk, MMED is more volatile compared to BTMD. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check BTMD's competition here
MMED vs DCGO Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, DCGO has a market cap of 56.7M. Regarding current trading prices, MMED is priced at $14.26, while DCGO trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas DCGO's P/E ratio is -0.30. In terms of profitability, MMED's ROE is -0.09%, compared to DCGO's ROE of -0.89%. Regarding short-term risk, MMED is more volatile compared to DCGO. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check DCGO's competition here
MMED vs ALR Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, ALR has a market cap of 44.2M. Regarding current trading prices, MMED is priced at $14.26, while ALR trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas ALR's P/E ratio is -1.11. In terms of profitability, MMED's ROE is -0.09%, compared to ALR's ROE of -0.15%. Regarding short-term risk, MMED is more volatile compared to ALR. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check ALR's competition here
MMED vs PIII Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, PIII has a market cap of 33.1M. Regarding current trading prices, MMED is priced at $14.26, while PIII trades at $10.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas PIII's P/E ratio is -0.26. In terms of profitability, MMED's ROE is -0.09%, compared to PIII's ROE of +1.85%. Regarding short-term risk, MMED is less volatile compared to PIII. This indicates potentially lower risk in terms of short-term price fluctuations for MMED.Check PIII's competition here
MMED vs IMAC Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, IMAC has a market cap of 33.1M. Regarding current trading prices, MMED is priced at $14.26, while IMAC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas IMAC's P/E ratio is -2.27. In terms of profitability, MMED's ROE is -0.09%, compared to IMAC's ROE of +1183.61%. Regarding short-term risk, MMED is more volatile compared to IMAC. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check IMAC's competition here
MMED vs CCEL Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, CCEL has a market cap of 27.8M. Regarding current trading prices, MMED is priced at $14.26, while CCEL trades at $3.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas CCEL's P/E ratio is -10.78. In terms of profitability, MMED's ROE is -0.09%, compared to CCEL's ROE of +0.16%. Regarding short-term risk, MMED is more volatile compared to CCEL. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check CCEL's competition here
MMED vs CANO-WT Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, CANO-WT has a market cap of 19.3M. Regarding current trading prices, MMED is priced at $14.26, while CANO-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas CANO-WT's P/E ratio is N/A. In terms of profitability, MMED's ROE is -0.09%, compared to CANO-WT's ROE of -1.49%. Regarding short-term risk, MMED is less volatile compared to CANO-WT. This indicates potentially lower risk in terms of short-term price fluctuations for MMED.Check CANO-WT's competition here
MMED vs AIH Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, AIH has a market cap of 15.9M. Regarding current trading prices, MMED is priced at $14.26, while AIH trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas AIH's P/E ratio is -2.78. In terms of profitability, MMED's ROE is -0.09%, compared to AIH's ROE of +1.16%. Regarding short-term risk, MMED is less volatile compared to AIH. This indicates potentially lower risk in terms of short-term price fluctuations for MMED.Check AIH's competition here
MMED vs CANO Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, CANO has a market cap of 12.4M. Regarding current trading prices, MMED is priced at $14.26, while CANO trades at $2.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas CANO's P/E ratio is -0.01. In terms of profitability, MMED's ROE is -0.09%, compared to CANO's ROE of -1.49%. Regarding short-term risk, MMED is more volatile compared to CANO. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check CANO's competition here
MMED vs FTRP Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, FTRP has a market cap of 9.8M. Regarding current trading prices, MMED is priced at $14.26, while FTRP trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas FTRP's P/E ratio is -1.22. In terms of profitability, MMED's ROE is -0.09%, compared to FTRP's ROE of -0.62%. Regarding short-term risk, MMED is more volatile compared to FTRP. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check FTRP's competition here
MMED vs AMS Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, AMS has a market cap of 9.2M. Regarding current trading prices, MMED is priced at $14.26, while AMS trades at $1.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas AMS's P/E ratio is -6.30. In terms of profitability, MMED's ROE is -0.09%, compared to AMS's ROE of -0.06%. Regarding short-term risk, MMED is more volatile compared to AMS. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check AMS's competition here
MMED vs MODV Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, MODV has a market cap of 6.2M. Regarding current trading prices, MMED is priced at $14.26, while MODV trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas MODV's P/E ratio is -0.03. In terms of profitability, MMED's ROE is -0.09%, compared to MODV's ROE of +1.84%. Regarding short-term risk, MMED is more volatile compared to MODV. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check MODV's competition here
MMED vs GBNH Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, GBNH has a market cap of 5.5M. Regarding current trading prices, MMED is priced at $14.26, while GBNH trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas GBNH's P/E ratio is -0.06. In terms of profitability, MMED's ROE is -0.09%, compared to GBNH's ROE of +15.74%. Regarding short-term risk, MMED is less volatile compared to GBNH. This indicates potentially lower risk in terms of short-term price fluctuations for MMED.Check GBNH's competition here
MMED vs SYRA Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, SYRA has a market cap of 5.4M. Regarding current trading prices, MMED is priced at $14.26, while SYRA trades at $0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas SYRA's P/E ratio is -24.00. In terms of profitability, MMED's ROE is -0.09%, compared to SYRA's ROE of -0.08%. Regarding short-term risk, MMED is more volatile compared to SYRA. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check SYRA's competition here
MMED vs TOIIW Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, TOIIW has a market cap of 5.4M. Regarding current trading prices, MMED is priced at $14.26, while TOIIW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas TOIIW's P/E ratio is N/A. In terms of profitability, MMED's ROE is -0.09%, compared to TOIIW's ROE of +3.27%. Regarding short-term risk, MMED is more volatile compared to TOIIW. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check TOIIW's competition here
MMED vs RHE Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, RHE has a market cap of 5.2M. Regarding current trading prices, MMED is priced at $14.26, while RHE trades at $2.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas RHE's P/E ratio is -1.79. In terms of profitability, MMED's ROE is -0.09%, compared to RHE's ROE of -0.36%. Regarding short-term risk, MMED is more volatile compared to RHE. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check RHE's competition here
MMED vs RHE-PA Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, RHE-PA has a market cap of 5.2M. Regarding current trading prices, MMED is priced at $14.26, while RHE-PA trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas RHE-PA's P/E ratio is -0.09. In terms of profitability, MMED's ROE is -0.09%, compared to RHE-PA's ROE of +2.11%. Regarding short-term risk, MMED is less volatile compared to RHE-PA. This indicates potentially lower risk in terms of short-term price fluctuations for MMED.Check RHE-PA's competition here
MMED vs ATIP Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, ATIP has a market cap of 3M. Regarding current trading prices, MMED is priced at $14.26, while ATIP trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas ATIP's P/E ratio is -0.03. In terms of profitability, MMED's ROE is -0.09%, compared to ATIP's ROE of +2.05%. Regarding short-term risk, MMED is more volatile compared to ATIP. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check ATIP's competition here
MMED vs IMACW Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, IMACW has a market cap of 1.7M. Regarding current trading prices, MMED is priced at $14.26, while IMACW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas IMACW's P/E ratio is N/A. In terms of profitability, MMED's ROE is -0.09%, compared to IMACW's ROE of +1.05%. Regarding short-term risk, MMED is less volatile compared to IMACW. This indicates potentially lower risk in terms of short-term price fluctuations for MMED.Check IMACW's competition here
MMED vs TALKW Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, TALKW has a market cap of 770.6K. Regarding current trading prices, MMED is priced at $14.26, while TALKW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas TALKW's P/E ratio is N/A. In terms of profitability, MMED's ROE is -0.09%, compared to TALKW's ROE of +0.01%. Regarding short-term risk, MMED is less volatile compared to TALKW. This indicates potentially lower risk in terms of short-term price fluctuations for MMED.Check TALKW's competition here
MMED vs CCM Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, CCM has a market cap of 656K. Regarding current trading prices, MMED is priced at $14.26, while CCM trades at $4.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas CCM's P/E ratio is -1.43. In terms of profitability, MMED's ROE is -0.09%, compared to CCM's ROE of +0.07%. Regarding short-term risk, MMED is more volatile compared to CCM. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check CCM's competition here
MMED vs MNDR Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, MNDR has a market cap of 640.4K. Regarding current trading prices, MMED is priced at $14.26, while MNDR trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas MNDR's P/E ratio is -0.30. In terms of profitability, MMED's ROE is -0.09%, compared to MNDR's ROE of -0.46%. Regarding short-term risk, MMED is more volatile compared to MNDR. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check MNDR's competition here
MMED vs NIVF Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, NIVF has a market cap of 480.1K. Regarding current trading prices, MMED is priced at $14.26, while NIVF trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas NIVF's P/E ratio is 0.02. In terms of profitability, MMED's ROE is -0.09%, compared to NIVF's ROE of +0.33%. Regarding short-term risk, MMED is more volatile compared to NIVF. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check NIVF's competition here
MMED vs NVOS Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, NVOS has a market cap of 394.6K. Regarding current trading prices, MMED is priced at $14.26, while NVOS trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas NVOS's P/E ratio is -0.02. In terms of profitability, MMED's ROE is -0.09%, compared to NVOS's ROE of -0.81%. Regarding short-term risk, MMED is less volatile compared to NVOS. This indicates potentially lower risk in terms of short-term price fluctuations for MMED.Check NVOS's competition here
MMED vs BACK Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, BACK has a market cap of 151.4K. Regarding current trading prices, MMED is priced at $14.26, while BACK trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas BACK's P/E ratio is -0.01. In terms of profitability, MMED's ROE is -0.09%, compared to BACK's ROE of +1.05%. Regarding short-term risk, MMED is more volatile compared to BACK. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check BACK's competition here
MMED vs PIIIW Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, PIIIW has a market cap of 50K. Regarding current trading prices, MMED is priced at $14.26, while PIIIW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas PIIIW's P/E ratio is -0.01. In terms of profitability, MMED's ROE is -0.09%, compared to PIIIW's ROE of +1.85%. Regarding short-term risk, MMED is less volatile compared to PIIIW. This indicates potentially lower risk in terms of short-term price fluctuations for MMED.Check PIIIW's competition here
MMED vs NIVFW Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, NIVFW has a market cap of 45.5K. Regarding current trading prices, MMED is priced at $14.26, while NIVFW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas NIVFW's P/E ratio is N/A. In terms of profitability, MMED's ROE is -0.09%, compared to NIVFW's ROE of +0.33%. Regarding short-term risk, MMED is less volatile compared to NIVFW. This indicates potentially lower risk in terms of short-term price fluctuations for MMED.Check NIVFW's competition here
MMED vs IONM Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, IONM has a market cap of 313. Regarding current trading prices, MMED is priced at $14.26, while IONM trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas IONM's P/E ratio is N/A. In terms of profitability, MMED's ROE is -0.09%, compared to IONM's ROE of +5.28%. Regarding short-term risk, MMED is less volatile compared to IONM. This indicates potentially lower risk in terms of short-term price fluctuations for MMED.Check IONM's competition here
MMED vs TVTY Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, TVTY has a market cap of 0. Regarding current trading prices, MMED is priced at $14.26, while TVTY trades at $32.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas TVTY's P/E ratio is 19.06. In terms of profitability, MMED's ROE is -0.09%, compared to TVTY's ROE of +1.75%. Regarding short-term risk, MMED is more volatile compared to TVTY. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check TVTY's competition here
MMED vs TLMD Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, TLMD has a market cap of 0. Regarding current trading prices, MMED is priced at $14.26, while TLMD trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas TLMD's P/E ratio is -1.60. In terms of profitability, MMED's ROE is -0.09%, compared to TLMD's ROE of -0.46%. Regarding short-term risk, MMED is more volatile compared to TLMD. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check TLMD's competition here
MMED vs HNGR Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, HNGR has a market cap of 0. Regarding current trading prices, MMED is priced at $14.26, while HNGR trades at $18.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas HNGR's P/E ratio is 19.71. In terms of profitability, MMED's ROE is -0.09%, compared to HNGR's ROE of +0.52%. Regarding short-term risk, MMED is more volatile compared to HNGR. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check HNGR's competition here
MMED vs ATIP-WT Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, ATIP-WT has a market cap of 0. Regarding current trading prices, MMED is priced at $14.26, while ATIP-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas ATIP-WT's P/E ratio is N/A. In terms of profitability, MMED's ROE is -0.09%, compared to ATIP-WT's ROE of +2.05%. Regarding short-term risk, MMED is less volatile compared to ATIP-WT. This indicates potentially lower risk in terms of short-term price fluctuations for MMED.Check ATIP-WT's competition here
MMED vs SLHG Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, SLHG has a market cap of 0. Regarding current trading prices, MMED is priced at $14.26, while SLHG trades at $0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas SLHG's P/E ratio is -1.48. In terms of profitability, MMED's ROE is -0.09%, compared to SLHG's ROE of N/A. Regarding short-term risk, MMED is more volatile compared to SLHG. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check SLHG's competition here
MMED vs DVCR Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, DVCR has a market cap of 0. Regarding current trading prices, MMED is priced at $14.26, while DVCR trades at $10.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas DVCR's P/E ratio is 28.34. In terms of profitability, MMED's ROE is -0.09%, compared to DVCR's ROE of -0.15%. Regarding short-term risk, MMED is more volatile compared to DVCR. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check DVCR's competition here
MMED vs NFH Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, NFH has a market cap of 0. Regarding current trading prices, MMED is priced at $14.26, while NFH trades at $11.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas NFH's P/E ratio is -19.75. In terms of profitability, MMED's ROE is -0.09%, compared to NFH's ROE of -0.06%. Regarding short-term risk, MMED is more volatile compared to NFH. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check NFH's competition here
MMED vs TLMDW Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, TLMDW has a market cap of 0. Regarding current trading prices, MMED is priced at $14.26, while TLMDW trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas TLMDW's P/E ratio is N/A. In terms of profitability, MMED's ROE is -0.09%, compared to TLMDW's ROE of -0.46%. Regarding short-term risk, MMED is more volatile compared to TLMDW. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check TLMDW's competition here
MMED vs DCGOW Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, DCGOW has a market cap of 0. Regarding current trading prices, MMED is priced at $14.26, while DCGOW trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas DCGOW's P/E ratio is N/A. In terms of profitability, MMED's ROE is -0.09%, compared to DCGOW's ROE of -0.89%. Regarding short-term risk, MMED is more volatile compared to DCGOW. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check DCGOW's competition here
MMED vs KND Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, KND has a market cap of 0. Regarding current trading prices, MMED is priced at $14.26, while KND trades at $9.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas KND's P/E ratio is N/A. In terms of profitability, MMED's ROE is -0.09%, compared to KND's ROE of -0.53%. Regarding short-term risk, MMED is more volatile compared to KND. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check KND's competition here
MMED vs SLHGP Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, SLHGP has a market cap of 0. Regarding current trading prices, MMED is priced at $14.26, while SLHGP trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas SLHGP's P/E ratio is -30.38. In terms of profitability, MMED's ROE is -0.09%, compared to SLHGP's ROE of -0.48%. Regarding short-term risk, MMED is more volatile compared to SLHGP. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check SLHGP's competition here
MMED vs AFAM Comparison June 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.1B. In comparison, AFAM has a market cap of 0. Regarding current trading prices, MMED is priced at $14.26, while AFAM trades at $56.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -11.40, whereas AFAM's P/E ratio is N/A. In terms of profitability, MMED's ROE is -0.09%, compared to AFAM's ROE of +0.06%. Regarding short-term risk, MMED is more volatile compared to AFAM. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check AFAM's competition here